Matthew L Cooper
Overview
Explore the profile of Matthew L Cooper including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
1333
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shrestha N, Dee M, Chaturvedi P, Leclerc G, Mathyer M, Dufour C, et al.
Cancer Immunol Immunother
. 2024 Jul;
73(9):179.
PMID: 38960949
Adoptive cellular therapy (ACT) using memory-like (ML) natural killer (NK) cells, generated through overnight ex vivo activation with IL-12, IL-15, and IL-18, has shown promise for treating hematologic malignancies. We...
2.
Chandra T, Bajaj M, Iyer R, Chan S, Bardo D, Chen J, et al.
J Am Coll Radiol
. 2024 Jun;
21(6S):S326-S342.
PMID: 38823954
Urinary tract infection (UTI) is a frequent infection in childhood. The diagnosis is usually made by history and physical examination and confirmed by urine analysis. Cystitis is infection or inflammation...
3.
Bardo D, Gill A, Iyer R, Chan S, Cooper M, Dasgupta R, et al.
J Am Coll Radiol
. 2024 Jun;
21(6S):S310-S325.
PMID: 38823953
Soft tissue vascular anomalies may be composed of arterial, venous, and/or lymphatic elements, and diagnosed prenatally or later in childhood or adulthood. They are divided into categories of vascular malformations...
4.
Xiang J, Devenport J, Carter A, Staser K, Kim M, O Neal J, et al.
Leukemia
. 2023 Oct;
37(12):2448-2456.
PMID: 37798328
T-cell malignancies are associated with frequent relapse and high morbidity, which is partly due to the lack of effective or targeted treatment options. To broaden the use of CAR-T cells...
5.
ONeal J, Cooper M, Ritchey J, Gladney S, Niswonger J, Gonzalez L, et al.
Blood Adv
. 2023 Jul;
7(20):6009-6022.
PMID: 37399471
Multiple myeloma (MM), a malignancy of mature plasma cells, remains incurable. B-cell maturation antigen (BCMA) is the lead protein target for chimeric antigen receptor (CAR) therapy because of its high...
6.
Kim S, Lim S, Kim B, Ritchey J, Vij K, Prior J, et al.
Blood
. 2022 Dec;
141(8):945-950.
PMID: 36477272
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment for both malignant and nonmalignant hematologic disorders. However, graft-versus-host disease (GVHD) and malignant relapse limit its therapeutic success. We previously...
7.
Karmazyn B, Marine M, Wanner M, Cooper M, Delaney L, Jennings S, et al.
Child Abuse Negl
. 2022 Aug;
133:105823.
PMID: 35973310
Background: Indications for chest CT in evaluation of child abuse are unknown. Objective: Determine which groups of children can best benefit from chest CT. Participants And Setting: 10-year (1/2010 to...
8.
Ghobadi A, Landmann J, Carter A, Cooper M, Selli M, Chang J, et al.
Blood Adv
. 2022 Jul;
6(20):5634-5640.
PMID: 35858291
No abstract available.
9.
Kim M, Jayasinghe R, Devenport J, Ritchey J, Rettig M, ONeal J, et al.
Nat Commun
. 2022 Jun;
13(1):3296.
PMID: 35697686
Chimeric antigen receptor (CAR) T cell therapy is routinely used to treat patients with refractory hematologic malignancies. However, a significant proportion of patients experience suboptimal CAR T cell cytotoxicity and...
10.
Moore M, Gee M, Iyer R, Chan S, Ayers T, Bardo D, et al.
J Am Coll Radiol
. 2022 May;
19(5S):S19-S36.
PMID: 35550801
Crohn disease is an inflammatory condition of the gastrointestinal tract with episodes of exacerbation and remission occurring in children, adolescents, and adults. Crohn disease diagnosis and treatment depend upon a...